US10981950B2 - Therapeutic protein flow kit for a continuous purification system - Google Patents

Therapeutic protein flow kit for a continuous purification system Download PDF

Info

Publication number
US10981950B2
US10981950B2 US16/263,855 US201916263855A US10981950B2 US 10981950 B2 US10981950 B2 US 10981950B2 US 201916263855 A US201916263855 A US 201916263855A US 10981950 B2 US10981950 B2 US 10981950B2
Authority
US
United States
Prior art keywords
kit
flow
serum
flow kit
static mixer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/263,855
Other languages
English (en)
Other versions
US20200247844A1 (en
Inventor
Joanna Pezzini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pak Biosolutions Inc
Original Assignee
Pak Biosolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pak Biosolutions Inc filed Critical Pak Biosolutions Inc
Priority to US16/263,855 priority Critical patent/US10981950B2/en
Priority to EP20748801.6A priority patent/EP3917559B1/de
Priority to PCT/US2020/012387 priority patent/WO2020159672A1/en
Publication of US20200247844A1 publication Critical patent/US20200247844A1/en
Application granted granted Critical
Publication of US10981950B2 publication Critical patent/US10981950B2/en
Assigned to PAK BIOSOLUTIONS, INC. reassignment PAK BIOSOLUTIONS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PEZZINI, Joanna
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/40—Mixing liquids with liquids; Emulsifying
    • B01F23/45—Mixing liquids with liquids; Emulsifying using flow mixing
    • B01F23/451—Mixing liquids with liquids; Emulsifying using flow mixing by injecting one liquid into another
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed

Definitions

  • the present invention relates to a therapeutic protein flow kit for a continuous purification system.
  • therapeutic fluid serums containing antibodies, interferon or other therapeutic proteins are essential for the treatment of myriad autoimmune and inflammatory diseases.
  • the disorders associated with such treatment are many and often well-known, including crohn's disease, colitis, lupus, multiple sclerosis, psoriasis and others.
  • the mechanisms by which therapeutic proteins treat the manifestations of such disorders are varied and, to ensure an effective response in specifically targeted tissue, it is essential that a given serum be properly formulated to contain the appropriate target protein(s) in the appropriate concentration(s), without the presence of extraneous proteins or other types of contamination.
  • a common monoclonal antibody purification process will consist of a Protein A affinity chromatography step, a low pH viral inactivation step, an anion exchange step (membrane or chromatography), a virus filtration step, a cation exchange chromatography step, and a diafiltration and concentration step. These steps typically provide orthogonal means of removing impurities that include DNA, viruses, host cell proteins, product impurities, etc.
  • a traditional batch process would hold a 200 L batch in a 200 L tank between each of the described steps, in comparison to a 200 mL to 2 L vessel used in a continuous process.
  • Reduced flow rates of the process allow for reduced piping or tubing sizes from 1 ⁇ 2′′ to 1 ⁇ 8′′, for the same size batch. This reduction in equipment size provides new opportunities for flow kits that directly meet the needs of a continuous process.
  • a flow kit for production of a therapeutic protein serum will contain one or more vessels for mixing, with one or more inflow pathways for the addition of components, one or more pathways to allow for testing of contents and one or more pathways for extraction of the product.
  • the presence of each such pathway necessarily carries the risk of leakage of a percentage of valuable product, as well as the risk of ingress of one or more contaminating substances, such as dust, bacteria, viruses or chemicals.
  • the presence of such contaminants in a therapeutic serum introduced into a patient may produce results ranging from the inefficacy of the serum to the introduction of harmful substances into the patient's body.
  • a flow kit for the continuous purification of a therapeutic protein serum product made of plastic, forming a single, compact, integrated piece comprising a static mixer, a mixing vessel, a plethora of input and outlet lines for the products and the addition of adjusting or processing solutions, a pH probe connection and a sampling connection.
  • the flow kit as described herein, wherein the manufacturing process is taken from the group consisting of 3D printing, injection molding, low-pressure molding such as gas-assist molding or structural-foam molding, coinjection, in-mold polymerization, blow molding, shaped thermoforming or another similar method.
  • the flow kit as described herein, wherein the plastic is HP 3D High Reusability PA 12 or another commercially available plastic with similar characteristics.
  • the flow kit as described herein, wherein the kit is connected by flexible tubing to a separate purification device such as a filter or chromatography column.
  • the flow kit as described herein, wherein the kit is disposable.
  • the flow kit as described herein, wherein the kit is detachable, cleanable and reusable.
  • the flow kit as described herein, wherein the kit processes the therapeutic protein serum by optionally mixing with an adjustment solution(s) in the static mixer, delivering the serum to a separate purification device, then optionally mixing the serum with adjustment solution(s) in the mixing vessel.
  • a therapeutic protein serum continuous purification system comprising one or more powered pumps, multiple solution containers, multiple flow kits of claim 1 , such flow kits interspersed with multiple filters and/or chromatography columns and a collection vessel, each connected by flexible tubing.
  • a method of purifying a therapeutic protein serum comprising the steps of:
  • FIG. 1 is a line drawing evidencing a perspective view from the static mixer side of a flow kit for the purification of therapeutic protein serum.
  • FIG. 2 is a line drawing evidencing an alternate view from the mixing vessel side of the flow kit of FIG. 1 .
  • FIG. 3 is a line drawing evidencing a top view of the flow kit of FIG. 1 .
  • FIG. 4 is a line drawing evidencing a perspective view of the flow kit of FIG. 1 with arrows showing the fluid flow path.
  • FIG. 5 is a flow chart evidencing a therapeutic protein serum purification system comprising multiple flow kits as shown in the preceding figures.
  • the invention is a flow kit to be employed in the continuous purification of therapeutic protein serum.
  • a major point of novelty of the invention is the use of a single, integrated device comprising both a static mixer and mixing vessel, along with multiple lines and ports for the introduction of adjusting and processing solutions, as well as for ingress and egress of the product before, during and after processing.
  • the integral nature of the kit provides for a compact device that can be seated alone or in a bank of multiple kits, minimizing flow path links and thus utilizing far less lab bench space than with previous non-integral versions.
  • the compact design is enabled by vertical orientation of a static mixer and necessary probes, and the probes' direct attachment to the mixer via 3D printing of necessary ports. This enables the entire flow path to rest on top of a scale and stir plate in the lab.
  • Kits may be at least as small as 6.25 cm length, 4 cm width and 7.25 cm height, or as much as 10 times such size.
  • the flow kit dimensions are approximately 12.5 cm length ⁇ 8 cm width ⁇ 15.5 cm height.
  • a flow kit of such size can process 50 L cell culture (with 5 g/l titer) per day.
  • the mixing vessel should be sized such that, at the flow rates used, the residence time provides sufficient mixing to achieve a homogenous solution. Flow rates are determined by pressure limitations for a given tube diameter. Larger and smaller tubes and vessel sizes within the kit and without it may be used to increase or decrease the flow rate and to fit the space available for setup.
  • Ideal vessel volume sizes for the described flow kit may run from 0.2 ml to 200 L. In preferable range, such kit would accommodate from 250 ml to 5 L of fluid. In a more preferred range, the kit would accommodate 500 ml to 2 L.
  • kits can instead be laid out on a tabletop or rack in rows without further need for stabilization.
  • a system would comprise a power source, one or more powered pumps to move serum through the system, multiple flow kits and one or more filters or chromatography columns attached to each kit, with the last kit in the system flowing into a collection vessel.
  • a purification system involving multiple integral kit units would allow for each unit to be discretely removed and replaced with only a few seconds' disruption to the system's processing. Thus, the units themselves operate disposably should any given unit become clogged or otherwise nonfunctional.
  • the manufacturing process of the integral device is to be taken from the group comprising, without limitation, 3D printing, injection molding, low-pressure molding such as gas-assist molding or structural-foam molding, coinjection, in-mold polymerization, blow molding, shaped thermoforming or another similar commercially known method.
  • the material used for the flow kit must provide rigidity to allow for durability and the attachment of flexible tubing and/or the connection of other devices such as filters or probes, as well as acceptably low in toxicity.
  • the flow kit is made of USP Class VI plastic, which has been tested as safe for pharmaceutical processing use with an acceptable toxicity profile, for example, HP 3D High Reusability PA 12.
  • Such plastic also provides excellent chemical resistance which enables chemical sanitization with acid and base solutions.
  • Such material also has thermal properties allowing for sanitization with steam.
  • the kit is made of another known plastic exhibiting sufficient rigidity and durability and usable in one of the preferred methods of manufacture.
  • Available plastics especially useful in 3D printing include acrylonitrile butadiene styrene (ABS), polyactic acid (PLA), polyvinyl chloride (PVC), polyethylene terephthalate (PET), PET with T-glase (PETT), copolyesters such as PETG, and polystyrene or high-impact polystyrene (HIPS).
  • ABS acrylonitrile butadiene styrene
  • PLA polyactic acid
  • PVC polyvinyl chloride
  • PET polyethylene terephthalate
  • PET PET with T-glase
  • copolyesters such as PETG
  • HIPS high-impact polystyrene
  • Carbon fiber would also be a preferred material.
  • the material could be a commercially appropriate metal or alloy such as aluminum or stainless steel.
  • kits The fluid flow through the kit itself and through any system comprised of multiple kits will be initiated and maintained by one or more powered, external pumps.
  • a powered pump will generate pressure to push untreated serum into the initial flow kit, and additional pumps may be located between kits or between a kit and filter or chromatography column as needed.
  • the main components of the integral flow kit are a static mixer and instrument ports on one side and vented mixing vessel on the other, each embodied as a chamber within the kit body accessed by various channels (also referred to as lines) also within the kit body.
  • a static mixer As therapeutic protein serum product is introduced to the kit through an external input line, such line transmits the product directly into the static mixer space.
  • a separate input line for adjusting or processing solutions, such as acid, base or buffer also flows directly to the static mixer, wherein such solution(s) is mixed with the newly introduced serum product to achieve the desired pH, conductivity, or buffer concentration. Said mixture is then transported through a static mixer, through instrument and sample ports and to a port with a hose barb for transportation out of the kit and towards a separate purification device comprising either a filtration device or a chromatography column.
  • the purification technologies i.e. chromatography column or filtration device
  • a single flow kit can be used with a single chromatography column or filtration device or multiple columns or filters may be connected in series or parallel within a single flow kit (ex. a depth filter, 0.2 um filter to minimize bioburden, anion exchange filter and virus filter can all be connected in series without exceeding pressure limitations).
  • the therapeutic protein serum is redirected to the flow kit via flexible tubing connected to a mixing vessel input line, thereby flowing directly into the mixing vessel.
  • a separate mixing vessel solution input line designed to be sub-surface, is also located on the outer surface of the kit and can be attached to flexible tubing providing for input of further adjusting or processing solutions such as, but not limited to, acid or base.
  • this line can be used to neutralize the pH of the product or adjust the pH, conductivity or concentration of the product to meet the requirements of the subsequent step.
  • this line can be used to siphon diafiltration buffer to provide continuous diafiltration in combination with inline concentration membranes.
  • the mixing vessel also comprises a vent or filter attachment embodied as another line between the mixing vessel and the outer surface of the kit body, such vent to create a pressure break for a reduction or elimination of pressure within the mixing vessel.
  • a vent or filter attachment embodied as another line between the mixing vessel and the outer surface of the kit body, such vent to create a pressure break for a reduction or elimination of pressure within the mixing vessel.
  • the static mixer is used to adjust the serum to meet the pH, conductivity and concentration profile required to perform purification on the chromatography or filtration device. Then, the mixing vessel is used to adjust the pH, conductivity or concentration of the product after it leaves the purification device to ensure it is stable or to achieve the desired composition for the subsequent step or final product collection.
  • connection components of the flow kit such as connections for pH probes or sampling, are to be embodied as tri-clamp ports.
  • Such ports may be fitted with rubber or rubber-like gaskets to effect a leak-proof seal.
  • the ends of various input and outlet lines extending outward from the kit body each end in a flared port barb to allow for a tight overlay of flexible tubing for the fluid moving towards or away from the kit.
  • Such port barbs may be integral to the kit and overlayed with a layer of rubber or rubber-like plastic to create a tight seal with the flexible tubing, luer locks or similar known fluid transmission features.
  • the barbs themselves may be made of such rubber-like material. All such gaskets, o-rings, barbs or barb covers may be removable and replaceable with wear.
  • FIG. 1 shows a perspective view of a flow kit 100 for the purification of therapeutic protein serum as seen from the from the static mixer 110 side.
  • the therapeutic protein serum to be processed by the flow kit 100 is introduced through product input line 112 and flows directly into static mixer 110 .
  • adjusting or processing solutions can be added to static mixer solution input line 111 , which also flows directly into static mixer 110 .
  • An external pump pushes the mixture of serum and solutions through a static mixer, through a sampling connection 140 and a pH probe connection 130 , and finally out through a second end of such outlet line 113 , such second end also comprising a port barb to which another flexible tube (not pictured) can be attached, thereby directing the processed therapeutic protein serum to a separate purification technology device (not pictured), which will either consist of a filtration device or chromatography column.
  • the pH probe connection 130 is embodied as an open port into which a pH measuring device may be inserted and/or locked, to measure the pH level of the therapeutic protein serum after processing in the static mixer 110 .
  • the sampling connection 140 is embodied similarly as an open port into which a sampling device (not pictured) may be inserted and/or locked to collect a sample of the therapeutic protein serum after processing in the static mixer for further testing.
  • FIG. 2 shows a perspective view of the alternate, mixing vessel 120 side of the flow kit 100 of FIG. 1 .
  • Processed serum solution from the separate purification device (not pictured) is reintroduced to the kit via flexible tubing attached to the mixing vessel input line 122 , and thus directly into the mixing vessel 120 .
  • a vent 124 Also embodied as a line to the external surface of the kit and connected to the mixing vessel is a vent 124 , which can also be used as a filter attachment in certain embodiments.
  • a mixing vessel solution input line 121 preferably located sub-surface to enable siphoning for diafitration, which can be used to introduce further fluid for adjustment or processing of the serum product inside the mixing vessel, after which mixing the processed serum flows into a product output line 123 , for delivery to another kit (not pictured) for further processing or to a collection vessel (not pictured).
  • An auxiliary connection 150 embodied as a circular port, is also provided between the outside of the kit body and the mixing vessel, such auxiliary connection available for one or more uses, including but not limited to sample collection, pH probe connection, or insertion of a stir bar.
  • FIG. 3 shows a top view emphasizing the various points of connection on top of the flow kit 100 for the fluids to be put into and extracted from the kit.
  • the top of the flow kit comprises a product input line 112 for introduction of serum and a static mixer outlet line 113 for transmission of the serum after processing in the static mixer 110 to a filtration device or chromatography column (not pictured).
  • a static mixer input line 111 for the introduction of solutions to treat and purify the serum such as pH adjusting agents
  • a mixing vessel input line 121 for the introduction of treatment and purification agents
  • a product outlet line 123 for the outflow of treated serum product either to a collection vessel or another flow kit (not pictured).
  • the top of the flow kit comprises a mixing vessel input line 122 carrying processed serum from the filtration device or chromatography column (not pictured) into the mixing vessel for further processing, and a mixing vessel filter attachment 124 for the optional attachment of a vent filter or for venting purposes.
  • Each component evidenced on top of the flow kit is a port embodied as a barbed tube connection onto which a flexible tube or line may be overlaid.
  • Each such component is manufactured through 3 d printing, injection molding or a similar process as a part of the larger flow kit 100 and thus is integral to the invention.
  • the flared port barb 160 of each component provides a stable, anchoring platform around which a flexible plastic or rubber tube may be arranged to create a seal to prevent leakage or contamination as fluids are introduced into or extracted from the flow kit.
  • FIG. 4 shows another perspective view of the flow kit 100 embodiment of FIG. 1 , also including arrows indicating the flow pattern of fluids (not pictured) moving into and out of the flow kit.
  • arrows indicate the following movement: the therapeutic protein serum product moves in through product input line 112 , through static mixer 110 for processing and out through static mixer outlet line 113 to the filtration device or chromatography column, back in through mixing vessel input line 122 , through the mixing vessel 120 , and finally out through the product outlet line 123 and on to either a final collection vessel or to another flow kit for further processing.
  • the dotted arrows indicated pathways for input of adjusting or processing solutions into static mixer 110 through static mixer solution input line 111 and into mixing vessel 120 through mixing vessel solution input line 121 .
  • FIG. 5 shows a flow chart evidencing the flow patterns of serum through a system comprising the flow kits 100 and other devices pictured in FIG. 4 .
  • the fluid begins in a collection vessel 180 , is pumped by a pump 200 to a first flow kit 100 , thence to a purification device 190 comprising either a filter or chromatography column, back to the first flow kit, thence to a second flow kit 100 , thence to a second purification device, back to the second flow kit, and then to a final collection vessel 180 .
  • adjusting solutions are added optionally via one or two pumps 200 , each pumping solution from a solution container 210 .
  • Placement of pumps in the system may vary between different iterations, for example residing between the solution container or collection vessel and flow kit, or alternatively on the opposite side of the flow kit from such solution container or collection vessel. Additional steps comprising additional flow kits, purification devices, etc. may be added without limitation. Arrows in the chart evidence flexible tubing attaching the components. Additional components, such as pH probes or sampling devices, may optionally be attached to one or more flow kits and not pictured.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
US16/263,855 2019-01-31 2019-01-31 Therapeutic protein flow kit for a continuous purification system Active 2039-09-18 US10981950B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/263,855 US10981950B2 (en) 2019-01-31 2019-01-31 Therapeutic protein flow kit for a continuous purification system
EP20748801.6A EP3917559B1 (de) 2019-01-31 2020-01-06 Strömungskit für therapeutisches protein für ein kontinuierliches reinigungssystem
PCT/US2020/012387 WO2020159672A1 (en) 2019-01-31 2020-01-06 Therapeutic protein flow kit for a continuous purification system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/263,855 US10981950B2 (en) 2019-01-31 2019-01-31 Therapeutic protein flow kit for a continuous purification system

Publications (2)

Publication Number Publication Date
US20200247844A1 US20200247844A1 (en) 2020-08-06
US10981950B2 true US10981950B2 (en) 2021-04-20

Family

ID=71835945

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/263,855 Active 2039-09-18 US10981950B2 (en) 2019-01-31 2019-01-31 Therapeutic protein flow kit for a continuous purification system

Country Status (3)

Country Link
US (1) US10981950B2 (de)
EP (1) EP3917559B1 (de)
WO (1) WO2020159672A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458908B2 (en) 2020-11-30 2025-11-04 PAK Biosolutions Inc. End-to-end continuous purification system
DE102021107394B4 (de) * 2021-03-24 2025-08-28 Sartorius Stedim Biotech Gmbh Vorrichtung zur kontinuierlichen Vireninaktivierung
WO2024155639A1 (en) * 2023-01-17 2024-07-25 PAK Biosolutions Inc. End-to-end continuous purification system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4693834A (en) 1986-05-05 1987-09-15 Murex Corporation Transverse flow diagnostic kit
US20020110495A1 (en) 2001-01-05 2002-08-15 Denis Hunt Devices and methods for purification
US8012584B2 (en) * 2003-08-28 2011-09-06 Mitsubishi Rayon Co., Ltd. High-performance pressure vessel and carbon fiber for pressure vessel
US8920645B2 (en) 2005-12-07 2014-12-30 Tarpon Biosystems Inc. Disposable chromatography valves and system
US20150133636A1 (en) * 2012-06-29 2015-05-14 Emd Millipore Corporation Purification of Biological Molecules
WO2018210644A1 (de) * 2017-05-15 2018-11-22 Sartorius Stedim Biotech Gmbh Einwegsfiltrationsmodul, einwegsreinigungsmodul jeweils einsetzbar in ein modulares filtrationssystem

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109193B2 (en) * 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
CA2824404C (en) * 2011-01-06 2023-01-03 Meso Scale Technologies, Llc Assay cartridges for pcr analysis and methods of use thereof
RU2013148071A (ru) * 2011-04-01 2015-05-10 Президент Энд Феллоуз Ов Харвард Колледж Аналогичное диализу терапевтическое (dlt) устройство
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
EP2656892A1 (de) * 2012-04-23 2013-10-30 Merck Patent GmbH Chromatographieverfahren

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4693834A (en) 1986-05-05 1987-09-15 Murex Corporation Transverse flow diagnostic kit
US20020110495A1 (en) 2001-01-05 2002-08-15 Denis Hunt Devices and methods for purification
US8012584B2 (en) * 2003-08-28 2011-09-06 Mitsubishi Rayon Co., Ltd. High-performance pressure vessel and carbon fiber for pressure vessel
US8920645B2 (en) 2005-12-07 2014-12-30 Tarpon Biosystems Inc. Disposable chromatography valves and system
US20150133636A1 (en) * 2012-06-29 2015-05-14 Emd Millipore Corporation Purification of Biological Molecules
WO2018210644A1 (de) * 2017-05-15 2018-11-22 Sartorius Stedim Biotech Gmbh Einwegsfiltrationsmodul, einwegsreinigungsmodul jeweils einsetzbar in ein modulares filtrationssystem

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arnold, Lee, Rucker-Pezzini and Lee, Implementation of Fully Integrated Continuous Antibody Processing: Effects on Productivity and COGm, Biotechnology Journal, 2018; 1-10.
Rucker-Pezzini J, Arnold L, Hill-Byrne K, Sharp T, Avazhanskiy M, Forespring, C. Single pass diafiltration integrated into a fully continuous mAb purification process. Biotechnology and Bioengineering. 2018;1-9.

Also Published As

Publication number Publication date
US20200247844A1 (en) 2020-08-06
EP3917559A1 (de) 2021-12-08
EP3917559B1 (de) 2024-03-27
WO2020159672A1 (en) 2020-08-06
EP3917559A4 (de) 2022-11-02
EP3917559C0 (de) 2024-03-27

Similar Documents

Publication Publication Date Title
US10981950B2 (en) Therapeutic protein flow kit for a continuous purification system
US11040310B2 (en) Single-pass filtration systems and processes
JP6862000B2 (ja) Ｃｆｆ／ｔｆｆ使い捨て流路における再循環ループ
JP6605504B2 (ja) タンパク質溶液からバッファーまたは媒体を連続的に交換するための限外ろ過ユニット
ES2864721T3 (es) Disposición y proceso continuo de un biorreactor para la producción y captura de un biopolímero
US20240246056A1 (en) Manufacturing device for a pharmaceutical product
US11951241B2 (en) Peritoneal dialysis system and methods
JP2020507333A (ja) ヘルスケア製品の連続的処理方法における脱気
US11547957B2 (en) Method of maintaining narrow residence time distributions in continuous flow systems
JP7691496B2 (ja) 最終充填アセンブリおよび完全性試験の方法
JP2024020456A (ja) 一体型かつ連続した組換えタンパク質の製造
CN221130487U (zh) 一种连续病毒灭活系统
CN111111484A (zh) 一种协同连续pH灭活液混合系统及其应用
TW201840342A (zh) 從滅菌程序移除之非滅菌廢棄物
CN116963821A (zh) 用于单程逆流渗滤的系统和方法
Tarrach et al. Integration of large-scale chromatography with nanofiltration for an ovine polyclonal product
HK40008150A (en) Non-sterile waste removal from a sterile process

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: MICROENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO MICRO (ORIGINAL EVENT CODE: MICR); ENTITY STATUS OF PATENT OWNER: MICROENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: PAK BIOSOLUTIONS, INC., VIRGINIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PEZZINI, JOANNA;REEL/FRAME:058538/0906

Effective date: 20200707

FEPP Fee payment procedure

Free format text: SURCHARGE FOR LATE PAYMENT, MICRO ENTITY (ORIGINAL EVENT CODE: M3554); ENTITY STATUS OF PATENT OWNER: MICROENTITY

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: MICROENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, MICRO ENTITY (ORIGINAL EVENT CODE: M3551); ENTITY STATUS OF PATENT OWNER: MICROENTITY

Year of fee payment: 4